Drug Profile
Veliparib - Abbvie
Alternative Names: ABT 888; NSC 737664Latest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator Abbott Laboratories; University of Alabama at Birmingham
- Developer Abbott Laboratories; AbbVie; Georgetown University; National Cancer Institute (USA); Northwestern University; University of Alabama at Birmingham
- Class Amides; Antineoplastics; Benzimidazoles; Pyrrolidines; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Breast cancer; Fallopian tube cancer; HER2 negative breast cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
- Phase II/III Glioblastoma
- Phase II Brain metastases; Colorectal cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Malignant melanoma; Pancreatic cancer; Rectal cancer; Solid tumours; Testicular cancer
- Phase I/II Glioma; Head and neck cancer; Small cell lung cancer
- No development reported Lymphoma; Multiple myeloma; Prostate cancer
- Discontinued Liver cancer
Most Recent Events
- 25 Jan 2024 AbbVie completes a phase III trial in HER2-negative-breast-cancer (Combination therapy, Late-stage disease) in USA, Austria, Australia, Belgium, Finland, Portugal, Hungary, Latvia, Spain, Puerto Rico, Ukraine, Turkey, Taiwan, South Africa, Singapore, Russia, Romania, Poland, Norway, Netherlands, Mexico, Lithuania, South Korea, France, Israel, Germany, Estonia, Denmark, Czech Republic, Colombia, Chile, Canada, Belarus, UK, Sweden and Italy (PO) (NCT02163694) (EudraCT2014-000345-70)
- 30 Oct 2023 Abbvie terminates a phase III VELIA trial in Ovarian cancer, Fallopian tube cancer and Peritoneal cancer (Combination therapy, First-line therapy, Late-stage disease) in USA, Australia, Brazil, Denmark, Israel, Japan, South korea, New Zealand, Poland, Spain and United Kingdom (PO) due to business decision and not due to patient safety (NCT02470585)
- 20 Sep 2023 National Cancer Institute completes a phase II trial in Rectal cancer (Neoadjuvant therapy, Late-stage disease, First-line therapy, Combination therapy) in USA and Puerto Rico (PO) (NCT02921256)